# Travere Therapeutics, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Travere Therapeutics, Inc.). ## Overview Travere Therapeutics is a U.S.-based biopharmaceutical company focused on therapies for rare diseases, with commercial products in kidney and metabolic disorders. Its portfolio includes FILSPARI, Thiola, and Thiola EC, and it also develops earlier-stage candidates such as pegtibatinase. ## Products & services • FILSPARI (sparsentan) for IgA nephropathy • Thiola and Thiola EC for cystinuria • Rare-disease patient support and access services • Clinical development of pegtibatinase and other candidates - **FILSPARI** (78%) — Commercial kidney-disease therapy for adults with IgA nephropathy. - **Thiola / Thiola EC** (17%) — Commercial cystinuria treatments sold through specialty pharmacy channels. - **License and collaboration revenue** (5%) — Milestones, royalties, and related collaboration income from partners. - FILSPARI (sparsentan) for IgA nephropathy - Thiola and Thiola EC for cystinuria - Rare-disease patient support and access services - Clinical development of pegtibatinase and other candidates ## Customers Travere sells primarily to patients with rare kidney and metabolic diseases, with prescribing driven by specialists such as nephrologists and urologists. Because these therapies are dispensed through direct-to-patient and specialty pharmacy channels, access support, reimbursement assistance, and adherence services are an important part of the customer relationship. - **IgA nephropathy patients** (primary) — Adults with primary IgAN treated with FILSPARI through specialist prescribing and pharmacy support. - **Cystinuria patients** (primary) — Patients with cystinuria treated with Thiola and Thiola EC to reduce cystine stone formation. - **Specialist physicians** (primary) — Nephrologists and urologists who diagnose, prescribe, and monitor rare-disease therapies. - **Payers and pharmacy benefit managers** (secondary) — Organizations that determine reimbursement, prior authorization, and patient access conditions. - **Partner companies** (secondary) — Collaborators such as CSL Vifor that contribute milestones, royalties, and regional commercialization support. - Patients with IgA nephropathy who receive FILSPARI - Patients with cystinuria who receive Thiola or Thiola EC - Nephrologists who prescribe FILSPARI and manage kidney disease - Urologists and nephrologists who treat cystinuria - Payers and specialty pharmacies that influence access and dispensing ## Geography Travere is headquartered in the United States and generates most of its commercial activity there, where FILSPARI and Thiola are marketed and distributed. It also has international exposure through collaboration and regulatory arrangements tied to FILSPARI in Europe, which adds partner-driven revenue and geographic diversification. - **United States** (85%) — Primary market for commercial product sales and patient support services. - **Europe** (15%) — Mainly collaboration-related exposure tied to FILSPARI commercialization and milestones. - United States is the core commercial market for FILSPARI and Thiola - U.S. specialty pharmacy distribution supports direct patient access - European exposure comes mainly through FILSPARI collaboration arrangements - Commercial operations are centered on U.S. rare-disease specialists - Third-party manufacturers and service providers support global supply chain ## Strategy Travere’s strategy centers on commercializing FILSPARI in IgA nephropathy, defending and extending its rare-disease franchise, and supporting access through specialist-focused patient services. The company also seeks to advance pipeline assets such as pegtibatinase while using partnerships and third-party manufacturing to limit capital intensity. - **Grow FILSPARI in IgA nephropathy** (short-term) — FILSPARI is the core commercial growth driver and the main source of product revenue. - **Protect and manage the cystinuria franchise** (short-term) — Thiola and Thiola EC remain important but face generic competition and pricing pressure. - **Advance pipeline programs** (medium-term) — Pipeline assets provide future growth beyond the current commercial portfolio. - **Leverage partnerships and external manufacturing** (medium-term) — Outsourcing reduces the need for owned manufacturing infrastructure and supports flexibility. - Expand FILSPARI adoption in IgA nephropathy - Support access, reimbursement, and adherence through Travere TotalCare - Defend Thiola and Thiola EC in cystinuria against generic competition - Advance pegtibatinase and other rare-disease candidates - Use partners and outsourced manufacturing to scale without owned plants ## Risks Travere depends heavily on successful commercialization of FILSPARI and on physician, patient, and payer acceptance in a specialized rare-disease market. The company also faces generic competition in Thiola products, clinical development risk in its pipeline, and supply-chain dependence on third-party manufacturers and CROs. - **Commercialization risk for FILSPARI** [high] — Revenue depends on physician uptake, payer coverage, and sustained market acceptance in IgAN. - **Generic competition for Thiola products** [high] — Approved generics can reduce volume and pricing in the cystinuria franchise. - **Clinical development failure** [high] — Pipeline candidates may not achieve approval or may require additional studies. - **Third-party manufacturing dependence** [medium] — The company outsources API, packaging, and commercial supply, limiting direct control. - **CRO and investigator dependence** [medium] — Clinical timelines and data quality rely on external research partners. - FILSPARI adoption depends on specialist and payer acceptance - Thiola and Thiola EC face generic competition and erosion risk - Clinical trials may fail, delay, or produce weaker-than-expected results - Third-party manufacturers and CROs create execution and supply risk - Partner milestones and royalties can be lumpy and hard to forecast ## Accounting Travere’s reported revenue includes product sales, collaboration revenue, royalties, and milestone-based income, so timing of recognition can materially affect quarter-to-quarter results. Investors should also watch clinical trial accruals, inventory provisions, and estimates tied to collaboration arrangements, because these areas depend on management judgment and can move reported expenses and margins. - **Revenue recognition for milestones, royalties, and product sales** — Can cause volatility in reported revenue and mix - **Clinical trial accruals** — Can shift operating expense timing - **Inventory reserves** — Affects gross margin and cost of goods sold - **Collaboration accounting** — Can materially affect non-product revenue - Product sales and collaboration revenue are recognized under different rules - Milestones and royalties can create uneven quarterly revenue - Clinical trial accruals depend on estimates of work performed - Inventory and excess/obsolete provisions affect cost of goods sold - Third-party manufacturing costs flow through product cost accounting --- *Last updated: 2026-04-29T05:04:20.802476+00:00*